Nephrocare Names CFO Goenka Chief Risk Officer

Nephrocare Health Services Ltd has appointed Chief Financial Officer Prashant Goenka as its new Chief Risk Officer (CRO). Goenka will hold both roles simultaneously, effective April 3, 2026.

Key Appointment Details

Nephrocare Health Services is strengthening its governance by appointing Chief Financial Officer Prashant Goenka as Chief Risk Officer. The appointment, effective April 3, 2026, combines key financial and risk oversight under one leader. Goenka will continue as CFO, applying his expertise to both roles.

Why the Dual Role Matters

This move signals Nephrocare Health Services' proactive strategy to embed risk management further into its financial planning. Combining the CFO and CRO roles could lead to better-aligned decisions, ensuring financial care and risk control work together. For shareholders, this suggests a commitment to stronger corporate governance, potentially enhancing operational strength and financial stability.

Goenka's Background and Company Milestones

Prashant Goenka brings extensive experience from leadership roles at global financial firms like HSBC, JP Morgan Chase, and Bank of America, with over two decades in the industry. He studied at the University of Chicago's Booth School of Business and has managed budgets over $100 million for multinational units.

Nephrocare Health Services recently completed its IPO in December 2025, raising about ₹871.05 crore and listing on the BSE and NSE. It is India's and Asia's largest dialysis provider.

Key Changes from the Appointment

• Combined leadership for financial and risk management.
• Potentially more integrated strategic planning between finance and risk.
• Strengthened corporate governance through the CRO role.
• Goenka's global finance experience to enhance risk oversight.

Industry Context

While Nephrocare operates in specialized dialysis, its peers in broader Indian healthcare include Apollo Hospitals, Fortis Healthcare, and Max Healthcare. These larger companies often have dedicated risk functions, reflecting an industry trend toward strong oversight.

Company Metrics

Prashant Goenka's tenure as CFO occurred during the company's IPO and period of growth. The company's market cap was approximately ₹5,289.96 crore as of April 2, 2026.

What to Watch Next

• How the dual CFO-CRO role will be structured in practice.
• Future announcements on risk management initiatives.
• Nephrocare's performance after integrating these roles.
• Broader governance trends in Indian healthcare.